Related Experiment Video
Updated: Apr 28, 2026
06:07
Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
5.3K
Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events
Jana Burghaus-Zhang1, Carsten Schulz1, Egle Ramelyte2
1Department of Dermatology and National Center for Tumor Diseases, University Hospital Heidelberg, 69115 Heidelberg, Germany.
Current Oncology (Toronto, Ont.)
|April 27, 2026
Summary
Retreating patients with dermatological tumors using the same or different Programmed cell death protein 1 (PD-1) inhibitors after immune-related adverse events (irAEs) can be safe. This approach offers a viable option for improving therapy tolerance in these patients.
Area of Science:
- Oncology
- Immunology
- Dermatology
Background:
- Programmed cell death protein (ligand) 1 (PD-(L)1) inhibitors are standard treatments for skin cancers.
- While generally safe, 9-21% of patients experience severe immune-related adverse events (irAEs).
- Limited alternative treatments necessitate evaluating the safety of re-administering PD-(L)1 inhibitors post-irAEs.
Purpose of the Study:
- To assess the safety and efficacy of re-challenging patients with PD-(L)1 inhibitors after irAEs.
- To compare outcomes between re-exposure to the same PD-(L)1 inhibitor versus switching to a different one.
Main Methods:
- A multicenter, retrospective study involving patients with metastatic dermatological tumors.
- Patients received either the same or a different PD-(L)1 inhibitor following prior irAEs.
- Data collected from centers in Heidelberg, Zurich, and Frankfurt.
Main Results:
- 22 patients (median age 71) were analyzed.
- 13 patients (59%) were re-exposed to the same PD-(L)1 inhibitor; 6 (46%) developed irAEs (67% identical to prior).
- 9 patients (41%) received a different PD-(L)1 inhibitor; 4 (44%) developed irAEs (75% identical to prior).
Conclusions:
- Re-exposure to the same PD-(L)1 inhibitor after irAEs is a safe option.
- Switching to a different PD-(L)1 inhibitor is also a viable strategy post-irAEs.
- Both strategies offer a reasonable chance of improved therapeutic tolerance.
Related Concept Videos
01:30Drug Toxicity: Allergic Reactions
206
Drug-related allergies are immune-mediated responses triggered by the administration of pharmacological agents. These hypersensitivity reactions are classified based on the immune mechanisms involved. The four primary types—Type I, II, III, and IV—are mediated by different immunological pathways and exhibit distinct clinical manifestations.Type I Hypersensitivity/ IgE-Mediated Reactions: Immunoglobulin E (IgE) immediately mediates Type I hypersensitivity reactions. Upon initial...
206
01:20Desensitization and Tachyphylaxis
3.4K
Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
3.4K
01:26Pharmacokinetic–Pharmacodynamic Relationship: Exposure, Response and Effect
265
The pharmacokinetic-pharmacodynamic (PK-PD) relationship describes the intricate link between drug exposure, efficacy, and toxicity, forming the foundation for optimal dosing regimens. This relationship uses mathematical modeling to characterize drug concentration-effect dynamics, ensuring precise therapeutic outcomes.Exposure represents the pharmacokinetic aspect of the PK-PD relationship, denoting the drug amount that elicits a biological response. It is typically quantified by administered...
265
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
97
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
97
01:19Pharmacovigilance
2.0K
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
2.0K
01:27Allergic Drug Reactions
1.6K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.6K